Thyroid suppression test with L-thyroxine and [99mTc] pertechnetate.
OBJECTIVE
The thyroid suppression test is still used in some centres as an adjunt in the diagnosis of autonomous functioning thyroid nodules. With the purpose of minimizing the disadvantages of the original T3 suppression test, we have evaluated the efficacy of a method using L-thyroxine as TSH suppression agent and [99 mTc] pertechnetate as radiopharmaceutical.


METHODS
Open nonrandomized prospective study


METHODS
A control group of 15 normal volunteers (11 males, 4 females; 21-35 years, mean 26.4 years) and a patient group of 20 patients (18 females, 2 males; 27-83 years, mean 53.6 years) divided into 4 subgroups, were studied: 7 patients with autonomous functioning nontoxic nodules, 3 with autonomous functioning toxic nodules, 7 with Graves disease and 3 with nonautoimmune diffuse toxic goitre. Baseline thyroid uptake and imaging were begun 20 minutes after an intravenous injection of 370 MBq (10 mCi) of [99 mTc] pertechnetate. This was followed by a single daily intake of 2 microg/kg of L-thyroxine, for 10 days. Thyroid imaging and uptake were then repeated.


RESULTS
In the control group [99 mTc] pertechnetate uptake after L-thyroxine suppression had a mean reduction of 75.8 +/- 7.69% (58-87%) in comparison to the baseline level. All subjects were euthyroid by clinical and laboratory criteria and none complained of side-effects, despite significant suppression of TSH levels. In the patient group, thyroid uptake after suppression decreased in 10 patients (maximum reduction 39%), was unchanged in 2 patients and increased in the remaining 8 patients.


CONCLUSIONS
The method described was efficient for demonstration of autonomous thyroid tissue, since none of the patients showed significant reduction of thyroid uptake after L-thyroxine suppression compared with the control group. This test was as effective as the original T3 suppression test, but more convenient to the patient: no side-effects, ease of hormonal intake, low dosimetry and short stay in the nuclear medicine laboratory.
Ramos
C D
CD
Division of Nuclear Medicine, Department of Radiology, School of Medical Sciences, Campinas State University, Campinas, Brazil. cdramos@mn-d.com
Zantut-Wittmann
D E
DE
Tambascia
M A
MA
Assumpção
L
L
Etchebehere
E C
EC
Camargo
E E
EE
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D003864:Depression, Chemical; D005260:Female; D006042:Goiter / Q000175:diagnosis; D006111:Graves Disease / Q000175:diagnosis; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D013670:Sodium Pertechnetate Tc 99m; D013959:Thyroid Diseases / Q000175:diagnosis*; D013960:Thyroid Function Tests / Q000379:methods; D016606:Thyroid Nodule / Q000175:diagnosis; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine
D019275:Radiopharmaceuticals; D013972:Thyrotropin; D013670:Sodium Pertechnetate Tc 99m; D013974:Thyroxine